Sfoglia per Autore
In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study.
2005 BONIFAZI F.; BANDINI G.; STANZANI M.; PALANDRI F.; GIANNINI B.; ARPINATI M.; ROSTI G.; BACCARANI M.
Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization.
2005 PALANDRI F; BONIFAZI F; ROSSI C; FALCIONI S; ARPINATI M; GIANNINI MB; ANSALONI F; BANDINI G; BACCARANI M.
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia
2006 S. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Rondoni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccarani
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies
2006 Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.; Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G.
Decision making at diagnosis in chronic myeloid leukemia
2007 Baccarani M.; Palandri F.; Castagnetti F.; Pusiol A.
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables
2007 Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A.
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
2007 Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Party on CML.
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
2007 Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin R; Martinelli G; Baccarani M.
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
2007 Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandri F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G.
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance
2007 Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
2007 Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
2008 Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML.
Thyrosin kinase inhibitors: nilotinib
2008 Castagnetti F.; Palandri F.; Gugliotta G.; Poerio A.; Amabile M.; Soverini S.; Martinelli G.; Baccarani M.; Rosti G.
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
2008 Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
2008 Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F; De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML.
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura.
2008 Vianelli N; Palandri F; Catani L; Boschi L; Poggioli G; Giampalma E; Baccarani M.
In newly diagnosed chronic phase Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia patients, imatinib-resistant BCR-ABL mutations are already detectable at low levels but do not correlate with subsequent clinical outcome – A study by the GIMEMA ALL and GIMEMA CML Working Parties.
2009 Soverini S; Poerio A; Vitale A; Gnani A; Colarossi S; Castagnetti F; Palandri F; Paolini S; Papayannidis C; Amabile M; Iacobucci I; Lonetti A; Vignetti M; Mandelli F; Baccarani M; Foà R; Martinelli G.
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.
2009 Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucchesi A; Baccarani M; Vianelli N.
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response
2009 Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Rege-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. | BONIFAZI F.; BANDINI G.; STANZANI M.; PALANDRI F.; GIANNINI B.; ARPINATI M.; ROSTI G.; BACCARANI M. | 2005-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. | PALANDRI F; BONIFAZI F; ROSSI C; FALCIONI S; ARPINATI M; GIANNINI MB; ANSALONI F; BANDINI G; BACC...ARANI M. | 2005-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia | S. Soverini;G. Martinelli;S. Colarossi;A. Gnani;F. Castagnetti;G. Rosti;C. Bosi;S. Paolini;M. Ron...doni;P. P. Piccaluga;F. Palandri;P. Giannoulia;G. Marzocchi;S. Luatti;N. Testoni;I. Iacobucci;D. Cilloni;G. Saglio;M. Baccarani | 2006-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies | Soverini S.; Tasco G.; Grafone T.; Colarossi S.; Gnani A.; Rosti G.; Castagnetti F.; Palandri F.;... Rondoni M.; Poerio A.; Iacobucci I.; Amabile M.; Baccarani M.; Casadio R.; Martinelli G. | 2006-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Decision making at diagnosis in chronic myeloid leukemia | Baccarani M.; Palandri F.; Castagnetti F.; Pusiol A. | 2007-01-01 | HEMATOLOGY EDUCATION | - | 1.01 Articolo in rivista | - |
| Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables | Baccarani M.; Castagnetti F.; Iacobucci I.; Palandri F.; Pusiol A. | 2007-01-01 | - | Informa healthcare - Taylor & Francis publishers | 2.01 Capitolo / saggio in libro | - |
| Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase | Palandri F, Iacobucci I, Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA Working Par...ty on CML. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. | Palandri F; Amabile M; Rosti G; Bandini G; Benedetti F; Usala E; Angelucci E; Tiribelli M; Fanin ...R; Martinelli G; Baccarani M. | 2007-01-01 | BONE MARROW TRANSPLANTATION | - | 1.01 Articolo in rivista | - |
| Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. | Rosti G; Iacobucci I; Bassi S; Castagnetti F; Amabile M; Cilloni D; Poerio A; Soverini S; Palandr...i F; Rege Cambrin G; Iuliano F; Alimena G; Latagliata R; Testoni N; Pane F; Saglio G; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance | Martinelli G.; Iacobucci I.; Soverini S.; Palandri F.; Castagnetti F.; Rosti G.; Baccarani M. | 2007-01-01 | BIOLOGICS | - | 1.01 Articolo in rivista | Martinelli_Biologics2007.pdf |
| Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain | Soverini S; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga... PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M; Martinelli G. | 2007-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome | Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T,... Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Thyrosin kinase inhibitors: nilotinib | Castagnetti F.; Palandri F.; Gugliotta G.; Poerio A.; Amabile M.; Soverini S.; Martinelli G.; Bac...carani M.; Rosti G. | 2008-01-01 | HEMATOLOGY MEETING REPORTS | - | 1.01 Articolo in rivista | - |
| Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up | Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungo...lino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G, Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D, Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic Myeloid Leukemia | 2008-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. | Palandri F; Iacobucci I; Martinelli G; Amabile M; Poerio A; Testoni N; Soverini S; Castagnetti F;... De Vivo A; Breccia M; Specchia G; Abruzzese E; Martino B; Cilloni D; Saglio G; Pane F; Liberati AM; Rosti G; Baccarani M; GIMEMA Working Party on CML. | 2008-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.01 Articolo in rivista | - |
| Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. |
Vianelli N; Palandri F; Catani L; Boschi L; Poggioli G; Giampalma E; Baccarani M. |
2008-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.06 Abstract in rivista | - |
| In newly diagnosed chronic phase Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia patients, imatinib-resistant BCR-ABL mutations are already detectable at low levels but do not correlate with subsequent clinical outcome – A study by the GIMEMA ALL and GIMEMA CML Working Parties. | Soverini S; Poerio A; Vitale A; Gnani A; Colarossi S; Castagnetti F; Palandri F; Paolini S; Papay...annidis C; Amabile M; Iacobucci I; Lonetti A; Vignetti M; Mandelli F; Baccarani M; Foà R; Martinelli G. | 2009-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |
| Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. | Palandri F; Catani L; Testoni N; Ottaviani E; Polverelli N; Fiacchini M; De Vivo A; Salmi F; Lucc...hesi A; Baccarani M; Vianelli N. | 2009-01-01 | AMERICAN JOURNAL OF HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response | Palandri F; Iacobucci I; Soverini S; Castagnetti F; Poerio A; Testoni N; Alimena G; Breccia M; Re...ge-Cambrin G; Tiribelli M; Varaldo R; Abruzzese E; Martino B; Luciano L; Pane F; Saglio G; Martinelli G; Baccarani M; Rosti G. | 2009-01-01 | CLINICAL CANCER RESEARCH | - | 1.01 Articolo in rivista | - |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile